Pharmaceutical Executive: July/August 2024

Three pieces of coverage in this month’s issue of Pharmaceutical Executive explore the tipping point that's seemingly on the cusp in artificial intelligence.

Ken Keller, CEO of Daiichi Sankyo’s US business, reflects on the trials, triumphs, and lessons learned in steering the transformation of a legacy cardiovascular company into a global leader in oncology—advancing a vision for a reimagined future in cancer treatment.